Skip to content

AI ECG Algorithm for Detecting LV Systolic Dysfunction

Prospective Observational Cohort Study of Deep Learning-based ECG Algorithm for Detecting Left Ventricular Systolic Dysfunction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07636759
Enrollment
15000
Registered
2026-06-09
Start date
2026-01-01
Completion date
2027-12-31
Last updated
2026-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HF - Heart Failure

Keywords

Heart failure, ECG, Artificial Intelligence, Deep Learning

Brief summary

This prospective observational cohort study aims to evaluate the clinical performance of a deep learning-based electrocardiography (ECG) algorithm (DeepECG LVSD) for detecting left ventricular systolic dysfunction (LVSD), defined as left ventricular ejection fraction (LVEF) ≤40%, using transthoracic echocardiography as the reference standard. Approximately 15,000 adult patients undergoing both ECG and echocardiography within 30 days at Ajou University Hospital will be enrolled. Diagnostic performance will be assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. Secondary analyses will evaluate the association between AI-predicted LVSD and 30-day clinical outcomes, including all-cause mortality, emergency department visits, and heart failure rehospitalization.

Detailed description

Left ventricular systolic dysfunction (LVSD) is associated with an increased risk of heart failure, hospitalization, and mortality. Although transthoracic echocardiography is the standard method for assessing left ventricular ejection fraction (LVEF), its widespread use as a screening tool is limited by availability, cost, and the need for specialized personnel. Artificial intelligence (AI)-based electrocardiography (ECG) algorithms have emerged as promising tools for identifying patients with reduced LVEF using routinely acquired ECG signals. DeepECG LVSD is a deep learning-based ECG algorithm developed to detect LVSD (LVEF ≤40%) from standard 12-lead ECG recordings. Previous retrospective validation studies demonstrated high diagnostic performance; however, prospective clinical validation in real-world practice remains limited. The purpose of this prospective observational cohort study is to evaluate the diagnostic performance and clinical utility of DeepECG LVSD in adult patients undergoing both ECG and transthoracic echocardiography at Ajou University Hospital. Approximately 15,000 patients aged 19 years or older who have undergone ECG and echocardiography within 30 days will be enrolled. The primary objective is to assess the accuracy of the AI algorithm for detecting LVSD using echocardiographic LVEF as the reference standard. Diagnostic performance will be evaluated using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy. Secondary objectives include evaluating the association between AI-predicted LVSD and short-term clinical outcomes, including 30-day all-cause mortality, emergency department visits, and heart failure rehospitalization. Exploratory subgroup analyses will assess algorithm performance according to demographic and clinical characteristics, including age, sex, heart failure status, chronic kidney disease, hypertension, diabetes mellitus, and the interval between ECG and echocardiography. This study is designed as a minimal-risk observational study and will provide prospective evidence regarding the effectiveness of AI-enabled ECG screening for LVSD in routine clinical practice. Findings from this study may support broader implementation of AI-based ECG tools for the early identification of patients at risk for heart failure and reduced left ventricular systolic function.

Interventions

There is no intervention group

Sponsors

Ajou University School of Medicine
Lead SponsorOTHER
VUNO Inc.
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged ≥19 years. * Patients who underwent both transthoracic echocardiography and 12-lead electrocardiography (ECG) at Ajou University Hospital in the outpatient, inpatient, or emergency department setting. * ECG and echocardiography performed within 30 days of each other.

Exclusion criteria

* Interval between ECG and echocardiography greater than 30 days. * Missing or corrupted original ECG waveform data (XML or HL7 format). * Presence of an implanted cardiac device, including a permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device. * Missing age, sex, or left ventricular ejection fraction (LVEF) data.

Design outcomes

Primary

MeasureTime frameDescription
AUROC for detection of LVSD (LVEF ≤40%)During procedureDiagnostic performance including AUROC, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy.

Countries

South Korea

Contacts

CONTACTMOONSEUNG SOH, MD
mssoh7701@gmail.com+82-31-219-5111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 11, 2026